This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yki-Järvinen, H. Articles by Taskinen, M.-R. Search for Related Content PubMed PubMed Citation Articles by Yki-Järvinen, H. Articles by Taskinen, M.-R.

Effect of Obesity on the Response to Insulin Therapy in Noninsulin-Dependent Diabetes Mellitus

Department of Medicine, Division of Endocrinology and Diabetology, University of Helsinki (H.Y.-J., M.-R.T.), Helsinki; Kymenlaakso Central Hospital (L.R.), Kotka; the Department of Medicine, University of Turku (M.K., P.S., J.V.), Turku; Hatanpää Hospital (E.K., S.R.), Finnish Diabetes Center (S.S.), Tampere; Kuopio City Hospital (J.L., L.N.), Kuopio; Äänekoski Health Center (T.M.), Äänekoski; and Lappi Central Hospital (T.T.), Rovaniemi, Finland

Address all correspondence and requests for reprints to: Prof. Hannele Yki-Järvinen, M.D., University of Helsinki, Department of Medicine, Division of Endocrinology and Diabetology, Haartmanin-katu 4, FIN-00290 Helsinki, Finland. E-mail: ykijarvi{at}helsinki.fi

An initial improvement in glycemic control is often followed by gradual deterioration of glycemia during insulin treatment of patients with noninsulin-dependent diabetes mellitus (NIDDM). We examined the causes of such worsening in a 12-month follow-up analysis of 100 insulin-treated NIDDM patients in the Finnish Multicenter Insulin Therapy Study who were treated with either combination therapy with insulin or insulin alone. In the entire study group, glycemic control averaged 9.7 ± 0.2% at 0 months and 8.0 ± 0.1%, 8.0 ± 0.1%, 8.2 ± 0.1%, and 8.5 ± 0.2% at 3, 6, 9, and 12 months (P < 0.001 for each time point vs. 0 months). Glycemic control at 12 months was significantly worse than that at 3 (P < 0.001), 6 (P < 0.001), and 9 months (P < 0.02). Baseline body mass index was the most significant predictor of deterioration in glycemic control. During 1 yr, hemoglobin A_1c decreased almost 3-fold more (by 1.7 ± 0.2%; P < 0.001 vs. 0 months) in patients whose baseline weight was below the mean baseline body mass index of 28.1 kg/m² (nonobese patients) than in those whose weight exceeded 28.1 kg/m² (obese patients; 0.5 ± 0.2%; P = NS vs. 0 months; P < 0.01 vs. obese patients). Glycemic control improved similarly over 1 yr in the nonobese subjects and deteriorated similarly in the obese patients regardless of their treatment regimen. Insulin doses, per body weight, were similar in the nonobese and obese patients. The nonobese patients consistently gained less weight during 12 months of combination therapy with insulin (3.5 ± 0.6 kg at 12 months) than during insulin therapy alone (5.1 ± 0.6 kg; P < 0.05). The treatment regimen did not influence weight gain in the obese group, who gained 4.4 ± 1.0 kg during combination therapy with insulin and 4.5 ± 1.1 kg during insulin therapy alone. We reached the following conclusions: 1) after an initial good response, glycemic control deteriorates more in obese than in nonobese patients with NIDDM; 2) in obese patients, weight gain per se cannot explain the poor glycemic response to combination or insulin therapy, but it may induce a disproportionately large increase in insulin requirements because of greater insulin resistance in the obese than in the nonobese; 3) in nonobese patients, glycemic control improves equally during 1 yr with combination therapy with insulin and insulin alone, but combination therapy with insulin is associated with less weight gain than treatment with insulin alone; 4) weight gain appears harmful, as it is associated with increases in blood pressure and low density lipoprotein cholesterol.

This article has been cited by other articles:

				P. Hollander Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes Diabetes Spectr, July 1, 2007; 20(3): 159 - 165. [Abstract] [Full Text] [PDF]

				W.S. Leslie, C.R. Hankey, and M.E.J. Lean Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review QJM, July 1, 2007; 100(7): 395 - 404. [Abstract] [Full Text] [PDF]

				B. Kanna and N. Mishra Efficacy and Safety of Inhaled Insulin Therapy Ann Intern Med, April 4, 2006; 144(7): 533 - 533. [Full Text] [PDF]

				J. Karalliedde, A. Smith, and G. Viberti Determinants of Response to Insulin Therapy Following Failure of Oral Agents in Type 2 Diabetes Diabetes Care, October 1, 2005; 28(10): 2589 - 2590. [Full Text] [PDF]

				M. B. Davidson Starting Insulin Therapy in Type 2 Diabetic Patients: Does it really matter how? Diabetes Care, February 1, 2005; 28(2): 494 - 495. [Full Text] [PDF]

				A. E. Pontiroli, P. Pizzocri, M. C. Librenti, P. Vedani, M. Marchi, E. Cucchi, C. Orena, M. Paganelli, M. Giacomelli, G. Ferla, et al. Laparoscopic Adjustable Gastric Banding for the Treatment of Morbid (Grade 3) Obesity and its Metabolic Complications: A Three-Year Study J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3555 - 3561. [Abstract] [Full Text] [PDF]

				D. E. Kelley, G. A. Bray, F. X. Pi-Sunyer, S. Klein, J. Hill, J. Miles, and P. Hollander Clinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes: A 1-year randomized controlled trial Diabetes Care, June 1, 2002; 25(6): 1033 - 1041. [Abstract] [Full Text] [PDF]

				H. Yki-Järvinen Combination Therapies With Insulin in Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 758 - 767. [Full Text]

				S. Vehkavaara, J. Westerbacka, T. Hakala-Ala-Pietilä, A. Virkamäki, O. Hovatta, and H. Yki-Järvinen Effect of Estrogen Replacement Therapy on Insulin Sensitivity of Glucose Metabolism and Preresistance and Resistance Vessel Function in Healthy Postmenopausal Women J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4663 - 4670. [Abstract] [Full Text]

				S. Vehkavaara, S. Makimattila, A. Schlenzka, J. Vakkilainen, J. Westerbacka, and H. Yki-Jarvinen Insulin Therapy Improves Endothelial Function in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 545 - 550. [Abstract] [Full Text] [PDF]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]

				H. Yki-Jarvinen, L. Ryysy, K. Nikkila, T. Tulokas, R. Vanamo, and M. Heikkila Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial Ann Intern Med, March 2, 1999; 130(5): 389 - 396. [Abstract] [Full Text] [PDF]

				A. E. Pontiroli Is Insulin the Only Treatment for Obese NIDDM Patients Poorly Controlled By Oral Hypoglycemic Agents?b J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2215 - 2215. [Full Text]